Genetic Pathways to Glioblastoma
Генетические пути развития глиобластомы
2004-10-01
SCID: 54.1/aweb9jpd
Discuss with AI
EGFR amplificationTP53 mutationsglioblastomaloss of heterozygosity 10qprimary and secondary glioblastomas
Figures from the paper
Abstract (AI)
We conducted a population-based study on glioblastomas in the Canton of Zurich, Switzerland (population, 1.16 million) to determine the frequency of major genetic alterations and their effect on patient survival. Between 1980 and 1994, 715 glioblastomas were diagnosed. The incidence rate per 100,000 population/year, adjusted to the World Standard Population, was 3.32 in males and 2.24 in females. Observed survival rates were 42.4% at 6 months, 17.7% at 1 year, and 3.3% at 2 years. For all of the age groups, younger patients survived significantly longer, ranging from a median of 8.8 months (<50 years) to 1.6 months (>80 years). Loss of heterozygosity (LOH) 10q was the most frequent genetic alteration (69%), followed by EGFR amplification (34%), TP53 mutations (31%), p16(INK4a) deletion (31%), and PTEN mutations (24%). LOH 10q occurred in association with any of the other genetic alterations and was predictive of shorter survival. Primary (de novo) glioblastomas prevailed (95%), whereas secondary glioblastomas that progressed from low-grade or anaplastic gliomas were rare (5%). Secondary glioblastomas were characterized by frequent LOH 10q (63%) and TP53 mutations (65%). Of the TP53 mutations in secondary glioblastomas, 57% were in hotspot codons 248 and 273, whereas in primary glioblastomas, mutations were more equally distributed. G:C-->A:T mutations at CpG sites were more frequent in secondary than primary glioblastomas (56% versus 30%; P = 0.0208). This suggests that the acquisition of TP53 mutations in these glioblastoma subtypes occurs through different mechanisms.
Key Findings
1
In a population-based Zurich cohort, glioblastoma incidence was 3.32 per 100,000 person-years in males and 2.24 in females.
2
LOH 10q occurred with other alterations and predicted shorter survival, while primary glioblastomas predominated over secondary tumors (95% versus 5%).
3
LOH 10q was the most frequent alteration (69%), followed by EGFR amplification (34%), TP53 mutations (31%), p16INK4a deletion (31%), and PTEN mutations (24%).
4
Observed survival was poor, reaching 42.4% at 6 months, 17.7% at 1 year, and 3.3% at 2 years; younger patients survived longer.
5
Secondary glioblastomas more often carried TP53 mutations, including hotspot codons 248 and 273, and CpG-site G:C→A:T mutations than primary tumors, suggesting distinct mutational mechanisms.
Research Object
Glioblastomas in the population of the Canton of Zurich, Switzerland
Research Subject
The frequency, patterns, and survival effects of major genetic alterations in primary and secondary glioblastomas, including distinct TP53 mutation mechanisms
Publication Details
Publication Date
2004-10-01
Journal
Cancer Research
Publisher
American Association for Cancer Research
ISSN
0008-5472
Cited by
1575
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
Cited by7
An Integrated Genomic Analysis of Human Glioblastoma Multiforme2008
The Definition of Primary and Secondary Glioblastoma2012
Epidemiology of Glioblastoma Multiforme–Literature Review2022
Epidemiology and Outcome of Glioblastoma2017
Using the molecular classification of glioblastoma to inform personalized treatment2013
Genetic pathways to glioblastomas2005
Glioblastoma: Morphologic and Molecular Genetic Diversity2007